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Edited by Horst FeldmannAbstract In the past decades, a gradual increase in the resis-
tance to antibiotics has been observed, leading to a serious thread
for successful treatment of bacterial infections. This feature in
addition to diﬃculties in developing adequate drugs against
(tropical) diseases caused by parasites has stimulated the interest
in vaccines to prevent infections. In principle, various types of
cell surface epitopes, characteristic for the invading organism
or related to aberrant growth of cells, can be applied to develop
vaccines. The progress in establishing the structure of carbohy-
drate immuno-determinants in conjunction with improvements
in carbohydrate synthesis has rendered it feasible to develop
new generations of carbohydrate-based vaccines.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The development of vaccines based on carbohydrates has a
long history. As early as 1923, Heidelberger and Avery [1] de-
scribed a ‘soluble speciﬁc substance’, of pneumococci to con-
sist most likely of polysaccharides (PSs) and being typical for
the serotype. Francis and Tillett [2] noted that intradermal
injections of type-speciﬁc polysaccharides induced the develop-
ment of circulating antibodies for heterologous types of Pneu-
mococci. Later, Heidelberger et al. [3] established that
pneumococcal capsular polysaccharides could be used as vac-
cines, providing a long lasting immunity. Despite the potential
to apply such compounds as vaccines, the development of che-
motherapeutics and antibiotics has led to a loss of interest in
this application. Renewed interest for preventive vaccination
was induced by the steady increase in resistance towards anti-
biotics. In 1983, Pneumovax was introduced, being a capsu-
lar polysaccharide vaccine derived from 14 pneumonia
serotypes. Subsequently, Pneumovax 23 was presented con-
taining isolated polysaccharides from 23 serotypes out of theAbbreviations: CRM197, cross-reactive material of diphtheria toxoid;
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doi:10.1016/j.febslet.2006.03.053about 90 known. This vaccine gives in healthy adults (short
term) protection for about 90% of the infections by these
microorganisms. However, polysaccharides are poorly immu-
nogenic in persons of high-risk groups: (i) neonates and chil-
dren until the age of two; (ii) elderly and chronically ill
people; (iii) splenectomised patients; (iv) immuno-compro-
mised people e.g. HIV infected. The age-related response to
plain polysaccharides may also be structure dependent: in con-
trast to other capsular polysaccharides, those of group A Neis-
seria. meningitidis and pneumococci type 3 and 18C are good
immunogens in infants from 3 to 6 months. They induce pro-
tective IgG antibodies. In fact vaccines were prepared from
their capsular polysaccharides, e.g. against meningococcal
infections vaccines containing capsular polysaccharides from
the meningococcal types: A + C, A + C + W135 or A + C +
Y +W135. Polysaccharides are considered to give an immune
response independent of T cells; they stimulate B-cells to pro-
duce antibodies without the involvement of T-cells. However,
some zwitterionic capsular polysaccharides can activate
CD4+ T cells. These polysaccharides are processed to low
molecular weight carbohydrates by a nitric oxide-mediated
mechanism and presented to T cells through the MHCII endo-
cytic pathway [4]. Furthermore, tolerance could become a
problem.
In contrast to polysaccharides, glycoproteins are T-cell
dependent (TD) antigens, having a larger immune response
for the same antigens. Already in 1931, Avery and Goedel
[5] reported that covalent attachment of carbohydrates to a
suitable protein induced an enhanced immunogenicity com-
pared to the polysaccharides as such. In general, immunization
with neoglycoproteins consisting of capsule-derived carbohy-
drates coupled to an immunogenic protein provides a long
lasting protection to encapsulated bacteria for adults as well
as for persons at high risk and young children (for reviews
see: [6–8]). In addition to isolated polysaccharides, oligosac-
charides derived from the capsular polysaccharides by degra-
dation or obtained by total synthesis are eﬀective compounds
for the preparation of glycoconjugate vaccines. Such oligosac-
charides have the advantage that they can be puriﬁed to single
molecular species and thereby being good starting compounds
for the preparation of well-deﬁned vaccines. In general poly-
saccharides are intrinsically polydisperse in molecular mass.
Conjugation of these macromolecules will yield heterogeneous
mixtures of compounds.
In this mini review, the emphasis will be on some of the main
aspects of glycoconjugate vaccines, rather than comprising all
developments in this fast moving area.blished by Elsevier B.V. All rights reserved.
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2.1. Carrier protein
Any protein, to be used in conjugation procedures for the
preparation of vaccines or medical treatment, has as a general
prerequisite that it should be allowed and safe for human
administration. Proteins that have been applied to couple with
carbohydrates are e.g. tetanus and diphtheria toxoids, cross-
reactive material of diphtheria toxoid (CRM197) [9], key hole
limpet hemocyanin (KLH) and the outer membrane complex
of Neisseria meningitides [10]. A few other bacteria-derived
proteins were so far studied in the laboratory, only.
2.2. Coupling
For coupling of polysaccharides to a protein, chemical acti-
vation of the polysaccharide and sometimes of both com-
pounds is necessary. The procedure to activate the
carbohydrate depends on the structure e.g.: reactive aldehyde
groups can be created from vicinal hydroxyl groups by perio-
date oxidation; carboxyl groups can be activated with carbo-
diimide followed by appropriate conversion; N-acetylamino
functions can be (partially) de-N-acetylated followed by acti-
vation with nitrous acid. Most of these reactions give rise to
a random creation of reactive centers in the polysaccharide.
Main reactive groups in proteins are the terminal amino group
and the e-amino functions of lysine. Random activation of the
reaction partners will allow the formation of conjugates,
however the structure of the reaction product may be rather
undeﬁned.
To create neoglycoconjugates having well deﬁned structures,
the introduction of the linkage between carbohydrate and pro-
tein should be as speciﬁc as possible. To avoid steric hindrance
between protein and glycan and to expose the immunogenic
epitopes, bifunctional spacer molecules can be introduced in
one or both of the reaction partners. Spacer molecules may
contain as reactive functions amino, carboxyl or thiol groups
[11].
In general, polysaccharides rarely present a singe molecular
species, but rather a family of closely related compounds, dif-
fering in degree of polymerization. Since the immunogenic epi-
tope comprises only part of the molecule, carbohydrate chains
as short as oligosaccharides can be used for the preparation of
eﬀective vaccines. Oligosaccharides can be obtained in pure
state through organic synthesis or by degradation of polysac-
charides. Coupling of oligosaccharides to proteins can be per-
formed in a rather speciﬁc route, aﬀording well-deﬁned
conjugates in a reproducible way [6–8].3. Glycoconjugate vaccines against bacterial infections
For several types of bacterial infections glycoconjugate vac-
cines can be based on fragments of capsular polysaccharides.
In particular, the following bacteria should be mentioned:
Streptococcus pneumoniae
Neisseria meningitidis
Haemophilus inﬂuenzae
Salmonella typhi
Shigella dysenteriae
Group B Streptococcus
Klebsiella pneumoniaeThe availability of methods to prepare speciﬁc oligosaccha-
ride structures opened the possibility to explore the relation be-
tween the oligosaccharide chain length and the potency of the
glycoconjugate as vaccine. We investigated the potency of syn-
thetic polysaccharide type-3 related di- tri- and tetrasaccha-
ride-CRM197 conjugates to provide protection against S.
pneumoniae type 3 infection. To this end the synthetic oligosac-
charides were coupled via the squarate method [12] to cross-
reactive material (CRM197) of modiﬁed diphtheria toxin in
various oligosaccharide/protein ratios. The products were ana-
lyzed for protein and carbohydrate content. The protective
immunity in mice was investigated in mice after two subcuta-
neous challenges with a three-week interval of 2.5 lg oligosac-
charide per mouse. All mice immunized with the tri- or
tetrasaccharide conjugates had IgG antibodies that bound
the capsular polysaccharide. After intraperitoneal injection of
a dose S. pneumonia lethal for control mice, all immunized
mice having formed polysaccharide type 3 speciﬁc antibodies
survived. Here, a correlation was found between polysaccha-
ride speciﬁc antibodies and protective capacity of the conju-
gates [13] (see Table 1).
The results ﬁt well to previous studies [14,15], wherein it was
shown that a hexasaccharide derived from polysaccharide type
3 coupled without spacer as a pentasaccharide to KLH was
capable of inducing protective immunity against type 3 pneu-
mococci in mice.
In a study on the immunogenicity and protective capacity of
S. pneumoniae 6B capsular polysaccharide derived di-(Rhaa1-
4-Rib-ol-5P-), tri- (Rib-ol-5P-2Gala1-3Glc-) and tetrasaccha-
ride (Rhaa1-4-Rib-ol-5P-2Gala1-3Glc-) conjugated to KLH,
we have found that the di- and tetrasaccharide (one repeating
unit) conjugates contain already epitopes capable of inducing
6B-speciﬁc, fully protective antibodies in rabbits and mice,
respectively [16].
In an investigation of a vaccine against S. dysenteriae type 1,
a series of speciﬁc, synthetic oligosaccharides was prepared on
the basis of the tetrasaccharide repeating unit of the O-speciﬁc
polysaccharide. The oligosaccharides were coupled to human
serum albumin and the conjugates were applied as vaccines
[17]. A clear inﬂuence was observed of chain lengths. The
octa-, dodeca-, and hexadeca-saccharides were immunogenic,
without adjuvant. Interestingly, the oligosaccharide conjugates
induced higher anti O-speciﬁc IgG levels than the conjugate of
the native O-speciﬁc polysaccharide. However, the tetrasac-
charide representing a single repeating unit was not eﬀective.
Also oligosaccharide loading of the protein is a relevant factor,
it should not be too high, nor too low.
The development of a synthetic conjugate vaccine against H.
inﬂuenzae type B provides an interesting example of the po-
tency of present day methodology. Peeters et al. [18] had
shown that conjugates of tri- and tetrameric 3-b-D-ribose-(1-
1)-ribitol-5-phosphate and tetanus or diphtheria toxoid aﬀor-
ded anti capsular-polysaccharide responses with an increasing
IgG/IgM ratio in adult mice and monkeys. Chong et al. [19]
have chosen a diﬀerent approach. They coupled oligosaccha-
rides consisting of repeating units of the H. inﬂuenzae type
B polysaccharide to synthetic peptides containing potent T-
helper cell determinants and B-cell epitopes. The conjugate
provided T-help and the carbohydrate hapten became T-cell-
dependent. In an infant rat model, the raised antibodies were
protective against H. inﬂuenzae type B infection. Optimal
results were obtained for the trimeric repeating unit. An break-
Table 1
Groups of 4 female BALB/c mice were immunized subcutaneously with 2.5 lg saccharide as a protein conjugate
Conjugate 10log IgG serum titers before infection in
individual mice
Survival time in days of individual mice
CRM <2 <2 <2 n.t. 2 3 3 n.t.
CRM-Glc <2 <2 <2 <2 3 3 3 3
CRM-GlcA <2 <2 <2 <2 3 >14 >14 3
Buﬀer <2 <2 <2 n.t. 3 3 3 n.t.
CRM-Di 1 4.0 4.3 <2 4.2 >14 >14 4 >14
CRM-Di 2 2.8 3.1 <2 3.2 >14 >14 2 >14
CRM-Tri 1 4.6 4.0 3.4 3.7 >14 >14 >14 >14
CRM-Tri 2 4.7 4.0 4.7 4.5 >14 >14 >14 >14
CRM-Tri 3 4.5 4.3 4.4 4.3 >14 >14 >14 >14
CRM-Tetra 1 4.5 4.6 4.1 4.3 >14 >14 >14 >14
CRM-Tetra-2 3.4 4.1 4.7 3.4 >14 >14 >14 >14
CRM-Tetra 2 (0.25 lg) n.t. <2.0 2.6 3.4 n.t. >14 >14 >14
CRM-Tetra-3 4.5 4.4 3.9 3.8 >14 >14 >14 >14
Control mice received CRM197 alone, CRM197 coupled to the monosaccharides Glc and GlcA or buﬀer solution. One group received 1/10 of the dose
of CRM-Tetra 2 (0.25 lg). A similar booster was given 3 weeks after the ﬁrst injection. Blood samples were taken 2 weeks before the challenge and
each sample was tested for IgG recognizing PS3. After 7 weeks a peritoneal challenge with 20 LD50 dose of type 3 S. pneumoniae. Survival was
recorded daily for 14 days. n.t. = not tested [13].
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ceeded in preparing a synthetic, commercial vaccine consisting
of synthetic oligosaccharides with an average of eight repeat-
ing units conjugated to human serum albumin, being safe for
human administration. The vaccine was evaluated in extensive
clinical trials in Cuba. The long-term protection was adequate.
This result indicates that for the production of vaccines the
synthesis of oligosaccharides is commercially feasible.
In summary, various oligosaccharide-conjugate vaccines
based on the capsular or O-speciﬁc polysaccharides exhibit
good immunogenic properties. However, this feature cannot
easily be related to chain length and/or saccharide density on
the carrier molecule. These aspects remain problems that re-
quire a large number of comparative, empirical approaches.
Anyhow, the synthesis of clearly deﬁned molecular entities will
render possible the study of the inﬂuences of these parameters
as well as of the characterization of the eﬀects of diﬀerent car-
rier molecules.4. Glycoconjugate vaccines against protozoan parasites
The principle of attacking invaders on the basis of unique
cell surface carbohydrates is in principle universally applicable.
In practice, it is not easy to develop vaccines that provide com-
plete protection to any kind of invader. The situation for anti
parasites vaccines is more complicated than for vaccines direc-
ted against encapsulated bacteria. These parasites are geneti-
cally and biologically complex organisms. Fundamental
studies are needed to gain insight into the processes like the
control of immune responses and the induction of appropriate
immunological memory [21]. In the framework of this review,
only some studies will be mentioned that are directed towards
glycoconjugate vaccines. Accepting these restrictions, interest-
ing developments can be noted with regard to diseases like ma-
laria, toxoplasmosis and leishmaniasis that are caused by
protozoan parasites. For malaria caused by Plasmodium falci-
parum, the attention is focused on the involvement of glycosyl-
phosphatidylinositol anchors (GPIs) in signal transductionprocesses and on the possibility to employ such speciﬁc
compounds as targets [22–24]. In this context the following
GPI-anchor-related compound was synthesized: NH2CH2-
CH2PO4(Mana1-2)6(Mana1-2Mana1-6Mana1-4)GlcNH2a1-
6myo-ino-sitol1,2 cyclic phosphate.
The product was then coupled to ovalbumin or to KLH and
the obtained conjugate was applied for administration to mice
to be studied as potential vaccines. Signiﬁcant protection was
observed against malarial acidose, pulmonary oedema, cere-
bral syndrome and mortality. It seems thereby that the stage
of lead compounds for vaccine development has been attained.
Furthermore, the synthetic compounds oﬀer the possibility to
investigate various basic immunological problems in relation
to malaria.
Toxoplasma gondii is a protozoan parasite that is responsi-
ble for toxoplasmosis in man. Also for this organism the GPIs
are interesting targets. The parasite contains in addition to the
more common compound: (NH2CH2CH2PO4)Mana1-2Man-
a1-6(GalNAcb1-4)Mana1-4GlcNH2a1-myo-inositol-P04-lipid,
the interesting novel GPI related compound [25]: (NH2CH2-
CH2PO4)Mana1-2Mana1-6(Glca1-4GalNAcb1-4)Mana1-4G
lcNH2a1-myo-inositol-P04-lipid.
Both compounds occur with and without terminal ethanol-
amine. Remarkably, only GPIs carrying the Glca1-4Gal-
NAcb1-4 side chains are immunogenic in humans. By
experiments that comprise also synthetic compounds [26], it
was shown that T. gondii GPIs are bioactive compounds that
participate in the production of TNFa during toxoplasmal
pathogenis. It is worthwhile to investigate to which extent a
vaccine prepared on the basis of these GPIs can be suitable
to prevent infection.
The leishmania parasite has very complex cell surface glyco-
conjugates [27], containing phosphosaccharide repeat units at
all stages of their life cycle. Lipophosphoglycan (LPG) repre-
sents one of these compounds and is considered to be a viru-
lence factor [28]. Since previous studies [29–31] had indicated
that puriﬁed LPG has a protective eﬀect on mice on challenge
with Leishmania major, this feature was further investigated by
Routier et al. [27]. They synthesized neoglycoproteins and neo-
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of various lengths viz.: (i)Galb1-4Mana-PO4H-6Galb1-4Man
a-PO4H-6Galb1-4Mana-O-(CH2)8CH‚CH2, (ii) a similar
compound, but extended at the penultimate Gal with a
Glcb1-3 residue and a PO4H inserted before the spacer and
(iii) one elongated with a Mana1-2Mana-PO4H unit. Immuno-
logical studies are still being carried out.
In a diﬀerent approach to develop a synthetic vaccine
against Leishmanisasis, the target was another part of the lipo-
phosphosaccharide, namely the tetrasaccharide cap. This sac-
charide was synthesized [32,33] and coupled through a spacer
to KLH: Mana1-2Mana1-2(Galb1-4)ManO(CH2)6NH–CO–
CH2-S-CH2CO-NH{KLH}.
In another attempt, the tetrasaccharide was linked to a
spacer and then conjugated to the immunostimulator tripalm-
itoyl-S-glycerylcysteine. These potential vaccines are tested in
an animal model. However, the World Health Organization
states in its report on ‘Parasitic Diseases’ that there is up
to now no vaccine for prevention of any form of Leishman-
iasis [34]. Apparently, there is still a long way to go for
obtaining vaccines that provide adequate immunity towards
infections.5. Glycoconjugate vaccines against cancer
Cancer vaccines are intended either to treat cancers (ther-
apeutic vaccines) or to delay or preferably prevent the devel-
opment of a relapse of cancer (prophylactic vaccines) after
any other form of (radical) therapy. Furthermore, preven-
tion of metastasis is an important aspect. Therapeutic vac-
cines are designed to stimulate the immune system to
recognize and attack human cancer cells, without doing
harm to normal cells. Obviously, the attack of self-antigens
should be avoided. The only cancer-related vaccine licensed
so far by the FDA is a prophylactic vaccine against hepatitis
B virus. Infection, with this virus is associated with liver
cancer.
Cancer cell antigens may be unique to individual tumors,
shared by several tumor types, or expressed by the normal
tissue from which the tumor grows. Some of these antigens
are carbohydrates and several trials are being carried out to
explore their possibilities to be used for the development of
vaccines. For example, on breast cancer cells Mucin-1
(MUC-1), NER-2/neu, carcino-embryonic antigen (CEA),
p53, Sialyl Tn (STn) and Globo H have been found. The
MUC-1 STn epitope: Neu5Aca2-6GalNAca1-O conjugated
to KLH (Biomira Inc. Edmonton, Alta., Canada), given in
combination with the adjuvant DETOX-B is currently under
investigation [35,36]. Although the results show the formation
of STn-speciﬁc IgM and IgG antibodies, so far no correlation
was found between antibody formation and clinical aspects
[37]. In addition, Tn-KLH is on a large scale being tested
in breast cancer patients. (For a review on anti-breast cancer
vaccines see [38].) NeuGcGM3 is another example of a com-
pound forming the basis for a possible vaccine against breast
cancer [39].
Globo H is a prominent epitope on prostate cancer cells. On
this basis a potential vaccine was prepared consisting of the
synthetic hexasaccharide chain of Globo H, linked to KLH.
The eﬀect is monitored by checking the prostate speciﬁc anti-
gen (PSA) concentration [40].Ganglioside molecules (e.g. GM2, GD2, GD3) are expressed
on several cancer cells. A vaccine that contains GM2 and GD2
is evaluated for the induction of antiGM2 and antiGD2 anti-
bodies, speciﬁcally directed towards melanoma cells (Progenics
Pharmaceuticals, Tarrytown, NY, USA) [41]. Furthermore, a
GM3 ganglioside conjugated vaccine is on trial for anti-mela-
noma eﬀects [42].
CEA is found in high levels in colorectal, lung, breast and
pancreatic cancers. Therefore, it could be a good starting point
for the development of a (semi) synthetic vaccine.
The examples given above represent just a small selection of
the wealth of studies that are currently in progress. They have
in common the search for anticancer vaccines based on carbo-
hydrate epitopes.6. In summary
In this mini review on glycoconjugate vaccines, the emphasis
is put on the character of the epitopes and on proteins as car-
rier molecules. It should be noted that liposomes [30,43] and
dendrimers [44,45] can be applied as carriers, but the detailed
discussion of these systems is beyond the scope of this review.
Since the large-scale synthesis of carbohydrates is no longer a
limiting factor, the preparation of carbohydrate-based and
structurally well-deﬁned vaccines has become feasible [20].
The screening for the optimal length of the carbohydrate
chain, the selection of the most suitable spacer and most eﬀec-
tive (protein) carrier are now realistic targets. The stability of
carbohydrates in biological systems is a point of continuous
attention. In this perspective, the synthesis can be mentioned
of analogues of GM2 and GM3 containing S-linked neurami-
nic acid and an amino terminated, truncated ceramide homo-
logue [46]. After conjugation to a protein these compounds are
tested as immunogens. The obvious advantage of these com-
pounds is their resistance against hydrolytic degradation.
For vaccines directed against bacterial polysaccharides sig-
niﬁcant progress has been made, leading to wide spread clinical
applications. With regard to a number of other pathogens,
breakthroughs can be expected.
The prevention of parasitic infections through immunization
is urgent, in particular in tropical regions. However, despite
many trials an eﬀective vaccine is not yet available. The devel-
opment of functional anticancer vaccines is even less straight-
forward. The immunological problems are complex and will
require further multidisciplinary research. The cancer speciﬁc
carbohydrate antigens are in principle good targets. To which
extent it could be proﬁtable to induce antibodies against an
ensemble of antigens remains to be investigated [47]. The indi-
vidual diﬀerences and biological variation could be limiting
factors in the clinical use. It should be noted that there might
exist other epitopes that are better suited to be used as starting
compounds for the preparation of anti cancer vaccines. The
selection of eﬀective adjuvants is an important aspect in the ac-
tual application of the glycoconjugate vaccines that needs fur-
ther consideration.References
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